

Hans-Georg Kopp

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11670811/hans-georg-kopp-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87
papers

4,331
citations

25
h-index

65
g-index

88
ext. papers

5,343
ext. citations

5.6
avg, IF

4.91
L-index

#	Paper	IF	Citations
87	Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. <i>Lancet, The</i> , 2019, 393, 1948-1957	40	675
86	Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. <i>Nature Medicine</i> , 2006, 12, 557-67	50.5	567
85	Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. <i>Cell Stem Cell</i> , 2009, 4, 263-74	18	464
84	The bone marrow vascular niche: home of HSC differentiation and mobilization. <i>Physiology</i> , 2005, 20, 349-56	9.8	348
83	Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. <i>Lancet Oncology, The</i> , 2018, 17, 1697-1708	21.7	336
82	Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. <i>Cancer Research</i> , 2009, 69, 7775-83	10.1	301
81	Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. <i>Cancer Research</i> , 2012, 72, 440-8	10.1	231
80	Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. <i>Current Opinion in Hematology</i> , 2006, 13, 175-81	3.3	173
79	Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1001-1007	2.2	129
78	Integrative genomic and transcriptomic analysis of leiomyosarcoma. <i>Nature Communications</i> , 2018, 9, 144	17.4	115
77	Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. <i>Blood</i> , 2005, 106, 505-13	2.2	95
76	Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. <i>Journal of Clinical Investigation</i> , 2006, 116, 3277-91	15.9	83
75	Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. <i>Blood</i> , 2013, 121, 723-33	2.2	67
74	GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. <i>Journal of Immunology</i> , 2012, 189, 154-60	5.3	67
73	Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. <i>Clinical and Experimental Metastasis</i> , 2010, 27, 141-9	4.7	55
72	Functional heterogeneity of the bone marrow vascular niche. <i>Annals of the New York Academy of Sciences</i> , 2009, 1176, 47-54	6.5	53
71	Modulation of natural killer cell anti-tumor reactivity by platelets. <i>Journal of Innate Immunity</i> , 2011, 3, 374-82	6.9	52

70	Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation. <i>Clinical and Developmental Immunology</i> , 2010 , 2010, 239083		50
69	Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. <i>Oncolmunology</i> , 2018 , 7, e1364827	7.2	42
68	Current insights into neutrophil homeostasis. <i>Annals of the New York Academy of Sciences</i> , 2012 , 1266, 171-8	6.5	42
67	Enhanced eryptosis contributes to anemia in lung cancer patients. <i>Oncotarget</i> , 2016 , 7, 14002-14	3.3	32
66	Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases. <i>Anticancer Research</i> , 2011 , 31, 4025-30	2.3	29
65	Neutrophil homeostasis and its regulation by danger signaling. <i>Blood</i> , 2014 , 123, 3563-6	2.2	27
64	The wolf in sheep's clothing: Platelet-derived "pseudo self" impairs cancer cell "missing self" recognition by NK cells. <i>Oncolmunology</i> , 2012 , 1, 557-559	7.2	27
63	Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3555-3564	2.2	26
62	Complete remission of relapsing high-grade angiosarcoma with single-agent metronomic trofosfamide. <i>Anti-Cancer Drugs</i> , 2006 , 17, 997-8	2.4	25
61	NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017 , 8, 755	17.4	24
60	Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. <i>American Journal of Clinical Dermatology</i> , 2008 , 9, 207-17	7.1	18
59	Shared cell surface marker expression in mesenchymal stem cells and adult sarcomas. <i>Stem Cells Translational Medicine</i> , 2013 , 2, 53-60	6.9	17
58	A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4-4	2.2	16
57	Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). <i>International Journal of Cancer</i> , 2020 , 147, 2493-2502	7.5	15
56	Impact of surgery in patients with metastatic soft tissue sarcoma: A monocentric retrospective analysis. <i>Journal of Surgical Oncology</i> , 2018 , 118, 167-176	2.8	14
55	Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11506-11506	2.2	10
54	Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients. <i>BMC Cancer</i> , 2016 , 16, 619	4.8	10
53	Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. <i>Nature Communications</i> , 2021 , 12, 7005	17.4	9

52	Modulation of Immune Responses by Platelet-Derived ADAM10. <i>Frontiers in Immunology</i> , 2020 , 11, 44	8.4	8
51	Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia. <i>Journal of Leukocyte Biology</i> , 2019 , 105, 531-538	6.5	7
50	Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4016-4016	2.2	6
49	Disease progression and defects in primary hemostasis as major cause of bleeding in multiple myeloma. <i>European Journal of Haematology</i> , 2020 , 104, 26-35	3.8	6
48	CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin. <i>European Journal of Radiology</i> , 2018 , 107, 175-182	4.7	6
47	Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 255-262	13.4	5
46	A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia. <i>Journal of Visualized Experiments</i> , 2018 ,	1.6	5
45	Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: A subgroup with improved overall survival.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 680-680	2.2	4
44	Low plasma protein Z levels are associated with an increased risk for perioperative bleedings. <i>European Journal of Haematology</i> , 2018 , 100, 403-411	3.8	3
43	Long-term results after transplantation of CD34+ selected (CellPro) versus unselected peripheral blood progenitor cells (PBPC) from related allogeneic donors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 1921-7	4.9	3
42	Pazopanib vs pazopanib + gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11004-11004	2.2	3
41	A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1027-1027	2.2	3
40	C-Cbl regulates c-MPL receptor trafficking and its internalization. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 12491-12503	5.6	3
39	Establishment and Characterization of a Sclerosing Spindle Cell Rhabdomyosarcoma Cell Line with a Complex Genomic Profile. <i>Cells</i> , 2020 , 9,	7.9	3
38	Long-term remission of refractory Rosai-Dorfman disease after salvage therapy with clofarabine in an adult patient. <i>Annals of Hematology</i> , 2019 , 98, 227-230	3	2
37	Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer (NSCLC) patient.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8051-8051	2.2	2
36	A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3049-3049	2.2	2
35	Oral intake of lipopolysaccharide regulates toll-like receptor 4-dependent granulopoiesis. <i>Experimental Biology and Medicine</i> , 2020 , 245, 1254-1259	3.7	1

34	Targeted Treatment of Esophagogastric Cancer. <i>Oncology Research and Treatment</i> , 2016 , 39, 788-794	2.8	1
33	Lymphocytes Are Dispensable In Neutrophil Homeostasis.. <i>Blood</i> , 2010 , 116, 2613-2613	2.2	1
32	Pseudoexpression of Glucocorticoid-Induced TNF-Related (GITR) Ligand Upon Coating of Cancer Cells by Platelets Impairs NK Cell Anti-Tumor Reactivity. <i>Blood</i> , 2010 , 116, 3193-3193	2.2	1
31	Transfer of MHC Class I by Coating Platelets Enables Tumor Cells to Evade NK Cell Immune Surveillance by Conferring a Pseudo Self Phenotype. <i>Blood</i> , 2010 , 116, 583-583	2.2	1
30	Platelets Impair NK Cell Immunosurveillance Of Metastasizing Tumor Cells By Altering Surface Expression and Shedding Of Ligands For The Activating Immunoreceptor NKG2D. <i>Blood</i> , 2013 , 122, 3488-3488	2.2	1
29	Phase I dose escalation of the oral histone deacetylase inhibitor (HDACi) resminostat in combination with FOLFIRI in colorectal cancer (CRC) patients: The SHORE trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3625-3625	2.2	1
28	A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer (RADIT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15535-e15535	2.2	1
27	FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: The RAMIRIS study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4132-TPS4132	2.2	1
26	Genetic Loss of NFAT2 Leads to CLL Transformation. <i>Blood</i> , 2015 , 126, 364-364	2.2	1
25	Genetic Loss of NFAT2 Induces Profound Acceleration of CLL in the TCL1 Mouse Model. <i>Blood</i> , 2012 , 120, 862-862	2.2	1
24	Overexpression and Aberrant Nuclear Translocation of NFAT2 in CLL. <i>Blood</i> , 2012 , 120, 3909-3909	2.2	1
23	A novel flow cytometry-based assay to measure compromised B cell receptor signaling as a prognostic factor in chronic lymphocytic leukemia. <i>Journal of Leukocyte Biology</i> , 2020 , 108, 1851-1857	6.5	1
22	PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapy.. <i>Cell and Bioscience</i> , 2022 , 12, 50	9.8	1
21	Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4079-4079	2.2	0
20	Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2020 , 11, 1995	8.4	0
19	Tie-2 Activation Is Required for Regeneration of Marrow Vasculature, Supporting Hematopoietic Reconstitution.. <i>Blood</i> , 2004 , 104, 1297-1297	2.2	
18	Newly Discovered Polymorphism in the CD34+ Stem Cell Specific AC133-P1 Promoter Linked to Leukemias.. <i>Blood</i> , 2004 , 104, 2002-2002	2.2	
17	Bone Marrow Osteoclasts Stain Positive with X-Gal: Implications for the Tracking of LacZ-Labelled Cells.. <i>Blood</i> , 2006 , 108, 4173-4173	2.2	

- 16 Centralized analysis of phase II ECG dataset of resminostat, an orally available histone-deacetylase inhibitor (HDACi).. *Journal of Clinical Oncology*, **2014**, 32, e13526-e13526 2.2
- 15 NFAT2 to regulate anergy induction in CLL through Lck.. *Journal of Clinical Oncology*, **2015**, 33, 7019-7019.2
- 14 EPAZ: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma of the Working Group Medical Oncology (AIO) and German Interdisciplinary Sarcoma Group (GISG).. *Journal of Clinical Oncology*, **2015**, 33, TPS10576-TPS10576 2.2
- 13 Interplay Between the Immune System and Colorectal Carcinoma - Towards Tumor-Specific Peptide-Based Vaccination for Any HLA-Type. *Blood*, **2015**, 126, 1027-1027 2.2
- 12 C-Cbl Regulates c-Mpl Receptor Trafficking and Its Internalization. *Blood*, **2015**, 126, 2388-2388 2.2
- 11 Unique Alterations in the Immunopeptidome of Colorectal Cancer Reflect Specific Transformations in Cancer-Associated Signaling Pathways and Reveal Tumor-Specific HLA-Ligand Modulations. *Blood*, **2016**, 128, 862-862 2.2
- 10 Knock-Down of the NFAT2 Long and Intermediate Isoforms Leads to CLL Acceleration. *Blood*, **2016**, 128, 4371-4371 2.2
- 9 NK Cell Anti-Tumor Reactivity Is Impaired by Platelet-Derived TGF- β through NKG2D Downregulation. *Blood*, **2008**, 112, 2859-2859 2.2
- 8 Analysis of Platelets in Solid Tumor Patients: Profound Changes and Unexpected Findings.. *Blood*, **2009**, 114, 4012-4012 2.2
- 7 Commensal Bacteria Are Dispensable in Neutropenia-Induced G-CSF Regulation. *Blood*, **2011**, 118, 4830-4830 2.2
- 6 Neutropenia Does Not Delay Lymphopoietic Regeneration in NODSCID β Mice. *Blood*, **2011**, 118, 4831-4831 2.2
- 5 First-salvage treatment in patients with recurrent or refractory advanced germ-cell cancer after cisplatin-based chemotherapy: A database of the German Testicular Cancer Study Group.. *Journal of Clinical Oncology*, **2013**, 31, 4559-4559 2.2
- 4 Aberrant NFAT2 signaling in chronic lymphocytic leukemia.. *Journal of Clinical Oncology*, **2013**, 31, 7019-7019 2.2
- 3 Expression of neurotrophins and their receptors in adult sarcomas.. *Journal of Clinical Oncology*, **2013**, 31, 10562-10562 2.2
- 2 Transcriptional Mistargeting Of NFAT2 In CLL. *Blood*, **2013**, 122, 4122-4122 2.2
- 1 NFAT2 Is a Critical Regulator Of Anergy Induction In CLL. *Blood*, **2013**, 122, 869-869 2.2